CoChat

Chronic Postsurgical Pain: Are We Closer to Understanding the Puzzle?

Buvanendran, Asokumar · 2012 · Anesthesia & Analgesia
Cited by 58

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

It is alarming that chronic postsurgical pain (CPSP) has assumed an epidemic proportion and deserves greater attention as the number of procedures being performed annually increases in the world. The consequence of CPSP can vary from mild to severe loss of quality of life. The first publication that identified surgery as a risk factor for CPSP appeared in 1998.1 This finding led to a dramatic increase in interest on this subject; searches on PubMed now reveal hundreds of publications on this topic. Although there are several publications on this emerging topic, the lack of a clear definition of CPSP makes comparisons of different studies and truly estimating the incidence of CPSP difficult. As an initial step, it is critical that a definition of CPSP based on scientific facts be formulated. Currently, it is accepted that CPSP should at least be of 2 months' duration2 after the surgical insult, which is an empirical time frame. Before a diagnosis of CPSP can be made, all other possible etiology for the postsurgical pain needs to be excluded. In addition, future CPSP trials should define in detail the location, characteristic, and consequence from CPSP on physical and social function.3 Kehlet et al. in 20064 outlined 3 possible mechanisms and pathophysiology for CPSP: a continuing inflammatory response; neuropathic pain; or predisposition to CPSP due to the patient's genetic makeup. If it is the latter, and the specific genetic determinant can be identified, patients undergoing elective surgery can be informed of the risk of CPSP. To achieve this, large clinical trials need to be performed to identify the genetic profile of patients predisposed to developing CPSP. In 2010 the Food and Drug Administration formed a panel called ACTION (Analgesic Clinical Trial Innovations, Opportunities and Network) and challenged the scientific community to develop preventive strategies for CPSP.5 Preoperative pain and6 psychological traits such as catastrophizing7 have recently been determined to be predictors of CPSP. Increased postoperative pain has also been suggested as an independent risk factor for CPSP. With regard to postoperative pain, differentiation between causality and association is exigent. It may well be that patients with severe acute postoperative pain experience greater spinal cord sensitization and therefore develop more persistent postsurgical pain. On the other hand, it may be postulated that patients with precursors of persistent postsurgical pain have severe acute postoperative pain because they are already developing CPSP. If CPSP is due to a continuing inflammatory process or is neuropathic, preventive measures could possibly be undertaken. The perioperative physicians (anesthesiologists) need to be in the leadership role to understand and institute measures to prevent CPSP. The incidence of neuropathic pain after total knee arthroplasty was determined to be 6%8 in a recent study. This is very similar to the value of 5.2% (control group) in a randomized controlled study examining the role of pregabalin for prevention of neuropathic pain (CPSP) after total knee arthroplasty published in 2010 with detailed examination.9 Similarly, estimates of neuropathic pain for different surgical procedures are 28% for thyroid surgery,10 19% for mastectomy,11 29% for thoracotomy,12 and 6% for hernia repair.13 One of the possible reasons for the wide variation in incidence of neuropathic pain after surgery may be due to the diagnostic test or questionnaires used in their studies. Future clinical trials need to only use validated neuropathic pain scales and standard diagnostic tests.14 The first line of therapy for neuropathic pain is gabapentenoids (α2δ ligand, voltage-dependent calcium channel inhibitors).15 Gabapentenoids have been used as an adjunct for acute postoperative analgesia and meta-analyses have demonstrated that they reduced opioid consumption and improved pain scores.16,17 A detailed systematic review and meta-analysis on the use of gabapentin and pregabalin for the prevention of CPSP was performed by Clarke et al.18 Of 567 clinical trials screened, 11 studies met the criteria for CPSP and Delphi criteria for quality assessment. Of the 11 studies, 8 used gabapentin and among them those demonstrating a reduction in CPSP involved larger preoperative doses (1200 mg of gabapentin) and a continuation of pharmacological therapy into the postoperative phase. Similarly, the 3 pregabalin studies that demonstrated a reduction in CPSP used a relatively large dose of 300 mg and continued this into the postoperative phase. Though there are no large scale equivalent analgesic dose conversion studies between gabapentin and pregabalin, some early studies equate 900 to 1500 mg of gabapentin to about 225 mg of pregabalin and 1500 to 2100 mg of gabapentin to about 300 of pregabalin.19 Given the mechanism of action of these 2 drugs, there is no doubt that multiple administrations of either drug are required to effectively

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1213/ane.0b013e318258b9f7

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 58

Metadata

Authors
Buvanendran, A.
Venue
Anesthesia & Analgesia
Published
2012-08
Volume
115
Issue
2
Pages
231-232
ISSN
0003-2999 (ISSN-L)
OpenAlex
W2068018886
Cited by
58
References
9
FWCI
3.01
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Chronic Postsurgical Pain: Are We Closer to Understanding the Puzzle? https://app.cochat.ai/papers/10.1213/ane.0b013e318258b9f7
The paper
Buvanendran, A. (2012). Chronic Postsurgical Pain: Are We Closer to Understanding the Puzzle? Anesthesia & Analgesia. https://doi.org/10.1213/ane.0b013e318258b9f7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.